Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-center, Randomized, Phase 2 Clinical Trial to Exploratively Evaluate the Efficacy and Safety of ASCA101 for the Treatment of Cachexia in Patients With Solid Tumor

NCT07168226 is registered in ClinicalTrials.gov with MetaFines as lead sponsor.

NCT NCT07168226
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07168226 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-center, Randomized, Phase 2 Clinical Trial to Exploratively Evaluate the Efficacy and Safety of ASCA101 for the Treatment of Cachexia in Patients With Solid Tumor
Lead sponsor
MetaFines
Phase
Phase 2
Overall status
Recruiting
Start date
May 8, 2026
Completion date
June 30, 2028
Enrollment
135 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

cachexia; cancer